Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
J Neurosurg Spine. 2012 Sep;17(1 Suppl):230-46. doi: 10.3171/2012.5.AOSPINE12115.
Using a systematic approach, the authors evaluated the current utilization, safety, and effectiveness of cellular therapies for traumatic spinal cord injuries (SCIs) in humans.
A systematic search and critical review of the literature published through mid-January 2012 was performed. Articles included in the search were restricted to the English language, studies with at least 10 patients, and those analyzing cellular therapies for traumatic SCI. Citations were evaluated for relevance using a priori criteria, and those that met the inclusion criteria were critically reviewed. Each article was then designated a level of evidence that was developed by the Oxford Centre for Evidence-Based Medicine.
The initial literature search identified 651 relevant articles, which decreased to 350 after excluding case reports and reviews. Evaluation of articles at the title/abstract level, and later at the full-text level, limited the final article set to 12 papers. The following cellular therapies employed in humans with SCI are reviewed: bone marrow mesenchymal and hematopoietic stem cells (8 studies), olfactory ensheathing cells (2 studies), Schwann cells (1 study), and fetal neurogenic tissue (1 study). Overall the quality of the literature was very low, with 3 Grade III levels of evidence and 9 Grade IV studies.
Several different cellular-mediated strategies for adult SCI have been reported to be relatively safe with varying degrees of neurological recovery. However, the literature is of low quality and there is a need for improved preclinical studies and prospective, controlled clinical trials.
采用系统方法评估细胞疗法治疗外伤性脊髓损伤(SCI)的当前应用、安全性和有效性。
对截至 2012 年 1 月中旬发表的文献进行系统检索和批判性评价。纳入研究为英文文献,至少包含 10 例患者,且分析外伤性 SCI 的细胞疗法。根据预先制定的标准评估纳入研究的相关性,符合标准的研究进行批判性评价。根据牛津循证医学中心的标准对每项研究进行证据水平分级。
最初的文献检索共识别出 651 篇相关文章,排除病例报告和综述后减少至 350 篇。通过标题/摘要评估和进一步的全文评估,最终文章集限定为 12 篇。本文回顾了以下在 SCI 患者中应用的细胞疗法:骨髓间充质和造血干细胞(8 项研究)、嗅鞘细胞(2 项研究)、施万细胞(1 项研究)和胎源性神经组织(1 项研究)。总体而言,文献质量非常低,仅有 3 篇为 III 级证据水平,9 篇为 IV 级研究。
已经报道了几种不同的细胞介导策略治疗成人 SCI,具有不同程度的神经恢复,相对安全。然而,文献质量较低,需要改善临床前研究和前瞻性、对照临床试验。